Japan is the third largest pharmaceuticals market in the world. As a result of the country's ageing population, there is a continuous increase in societal healthcare awareness. Japan has a number of internationally operating research companies that are actively looking for collaboration opportunities with new and innovative pharmaceutical companies. The healthcare and medical industries make up the majority of the biotechnology sector in Japan, and its expansion is an integral part of the Abe administration’s growth strategy. Over the last 30 years Japan’s biotechnology sector has grown rapidly and offers numerous opportunities for European exports of biopharmaceutical products and R&D cooperation
Japan continues to be Asia’s number-one country in biotech and pharma patents (13,748 listing at least one Japanese inventor, according to WIPO), as well as a firm number-two in R&D ($170.082 billion in 2015, according to OECD).
How can I access the Japanese market as a novel biopharmaceutical product's owner?Japan includes a huge market for biopharmaceutical products which is open for innovative products and services, also
This website and related activities are managed by the EU-Japan Centre for Industrial Cooperation, a joint venture between the European Commission's Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) and the Japanese Government's Ministry of Economy, Trade & Industry (METI).
No less than 300 web pages with up-to-date information on Japan, more than 170 reports available as well as a lot of detailed information on the Japanese business culture.